SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/A65F6EFF9DA4881D346ECBEBBAF6B23E2FA2D06AEB4735D4706184E6A4E1D5B2C708C2FADB4C35D3A0DC4DE8906AE0CD>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/A65F6EFF9DA4881D346ECBEBBAF6B23E2FA2D06AEB4735D4706184E6A4E1D5B2C708C2FADB4C35D3A0DC4DE8906AE0CD
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/A65F6EFF9DA4881D346ECBEBBAF6B23E2FA2D06AEB4735D4706184E6A4E1D5B2C708C2FADB4C35D3A0DC4DE8906AE0CD
http://www.w3.org/2000/01/rdf-schema#comment
"Data show that TET2 and ASXL1 pathogenic mutations are found in 8% of myeloproliferative neoplasms lacking JAK2 and MPL mutations whereas IDH1 IDH2 and c-CBL mutations are not detected in this subset of patients."
xsd:string
http://purl.uniprot.org/uniprot/#_1D593988659224641ED952AF34C50BFA72523954E52CC8266BB2B820D527EFB3325B1DBD4E4BE2DB6050FF2957B90BC8
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/A65F6EFF9DA4881D346ECBEBBAF6B23E2FA2D06AEB4735D4706184E6A4E1D5B2C708C2FADB4C35D3A0DC4DE8906AE0CD
http://purl.uniprot.org/uniprot/Q498B9
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A65F6EFF9DA4881D346ECBEBBAF6B23E2FA2D06AEB4735D4706184E6A4E1D5B2C708C2FADB4C35D3A0DC4DE8906AE0CD
http://purl.uniprot.org/uniprot/#_Q498B9-mappedCitation-21904853
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A65F6EFF9DA4881D346ECBEBBAF6B23E2FA2D06AEB4735D4706184E6A4E1D5B2C708C2FADB4C35D3A0DC4DE8906AE0CD